Home > Back to Publisher > Report Information

Ovarian Cancer - Pipeline Review, H1 2012

Global Markets Direct
January 23, 2012
418 Pages - SKU: GMD6775805

Abstract Table of Contents Search inside this report Related Reports

Ovarian Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2012', provides an overview of the Ovarian Cancer therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. 'Ovarian Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

A snapshot of the global therapeutic scenario for Ovarian Cancer.
A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Ovarian Cancer therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Introduction: Global Markets Direct Report Coverage; Ovarian Cancer Overview; Therapeutics Development; An Overview of Pipeline Products for Ovarian Cancer; Ovarian Cancer Therapeutics under Development by Companies; Ovarian Cancer Therapeutics under Investigation by Universities/Institutes; Late Stage Products; Comparative Analysis; Mid Clinical Stage Products; Comparative Analysis; Early Clinical Stage Products; Comparative Analysis; Discovery and Pre-Clinical Stage Products; Comparative Analysis; Ovarian Cancer Therapeutics - Products under Development by Companies; Ovarian Cancer Therapeutics - Products under Investigation by Universities/Institutes; Companies Involved in Ovarian Cancer Therapeutics Development; Johnson & Johnson; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Amgen Inc.; Sanofi-Aventis; AstraZeneca PLC; Eli Lilly and Company; Viralytics Ltd.; GlaxoSmithKline plc; Tekmira Pharmaceuticals Corp.; Genentech, Inc.; Nektar Therapeutics; Daiichi Sankyo Company, Ltd; Merck & Co., Inc.; Micromet, Inc.; Generex Biotechnology Corporation; Takeda Pharmaceutical Company Limited; Bio-Path Holdings, Inc.; Millennium Pharmaceuticals, Inc.; Novartis AG; Viventia Biotechnologies Inc.; TRACON Pharmaceuticals, Inc.; Advanced Cancer Therapeutics; Oncolix, Inc.; OHR Pharmaceutical Inc.; RECEPTA Biopharma S.A.; Kyowa Hakko Kirin Pharma, Inc.; Vaxonco; Sentinel Oncology Limited; Mebiopharm Co., Ltd.; VectorLogics, Inc.; ISA Pharmaceuticals B.V.; Gradalis Inc.; Oncozyme Pharma Inc.; Ovarian Cancer - Therapeutics Assessment; Assessment by Monotherapy Products; Assessment by Combination Products; Assessment by Route of Administration; Assessment by Molecule Type; Drug Profiles; AMG 386 - Drug Profile; Abagovomab - Drug Profile; OPAXIO - Drug Profile; MORAb-003 - Drug Profile; Paclical - Drug Profile; Telcyta - Drug Profile; NV06 - Drug Profile; Vargatef - Drug Profile; Tirazone - Drug Profile; Particulate Delivery - Drug Profile; Trabectedin - Drug Profile; Carboplatin + Thalidomide - Drug Profile; Amifostine Trihydrate - Drug Profile; Phenoxodiol + Carboplatin - Drug Profile; Bevacizumab + Carboplatin + Gemcitabine - Drug Profile; Carboplatin + Paclitaxel + Bevacizumab - Drug Profile; Carboplatin + Paclitaxel + Bevacizumab - Drug Profile; Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile; Carboplatin + Taxol - Drug Profile; Cisplatin + Taxol - Drug Profile; Carboplatin + Gemcitabine + Paclitaxel - Drug Profile; Carboplatin + Paclitaxel - Drug Profile; Paclitaxel + Carboplatin + Topotecan - Drug Profile; Carboplatin + Ifosfamide - Drug Profile; Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile; Carboplatin + Paclitaxel + Cediranib - Drug Profile; Carboplatin + Paclitaxel + Doxorubicin HCl Liposome - Drug Profile; Carboplatin + Paclitaxel + Gemcitabine - Drug Profile; Carboplatin + Topotecan Hydrochloride - Drug Profile; Carboplatin + Gemcitabine - Drug Profile; Carboplatin + Paclitaxel - Drug Profile; Carboplatin - Drug Profile; Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile; Sodium Thiosulfate - Drug Profile; Paclitaxel - Drug Profile; Taxol + Paraplatin - Drug Profile; AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile; AMG 386 + Paclitaxel - Drug Profile; Carboplatin + Paclitaxel - Drug Profile; Treosulfan - Drug Profile; Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile; Carboplatin + Liposomal Doxorubicin - Drug Profile; Ifosfamide + Paclitaxel - Drug Profile; Yondelis + DOXIL - Drug Profile; Avastin + Carboplatin + Paclitaxel - Drug Profile; Avastin + Carboplatin + Paclitaxel - Drug Profile; Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile; Gemcitabine + Carboplatin - Drug Profile; Telcyta + Paraplatin - Drug Profile; Topotecan - Drug Profile; Karenitecin - Drug Profile; CAELYX + Carboplatin - Drug Profile; Paclitaxel + Carboplatin - Drug Profile; Doxorubicin + Carboplatin + Paclitaxel - Drug Profile; Cisplatin - Drug Profile; Cyclophosphamide + Cisplatin - Drug Profile; Bevacizumab + Cisplatin + Paclitaxel - Drug Profile; EC145 + Doxil - Drug Profile; Cisplatin - Drug Profile; Cisplatin + Carboplatin - Drug Profile; Avastin - Drug Profile; Filgrastim + Doxorubicin + Ifosfamide - Drug Profile; Doxorubicin + Carboplatin - Drug Profile; Paclitaxel + Carboplatin - Drug Profile; Docetaxel + Carboplatin - Drug Profile; Paclitaxel + Carboplatin - Drug Profile; Oxaliplatin + Capecitabine - Drug Profile; Carboplatin + Taxol - Drug Profile; Irinotecan + Cisplatin - Drug Profile; Irinotecan + Cisplatin - Drug Profile; Taxol + Paraplatin + Bevacizumab - Drug Profile; cediranib - Drug Profile; Paclitaxel + Carboplatin + Epirubicin - Drug Profile; Irinotecan + Cisplatin - Drug Profile; Votrient - Drug Profile; Tarceva - Drug Profile; Paclitaxel + AZD0530 - Drug Profile; Cisplatin + Cyclophosphamide + Tamoxifen - Drug Profile; Bevacizumab + Carboplatin + Paclitaxel - Drug Profile; Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile; OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile; Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile; Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile; Carboplatin + Glutathione + Paclitaxel - Drug Profile; bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile; Carboplatin + Paclitaxel + Bevacizumab - Drug Profile; Cisplatin + Paclitaxel - Drug Profile; CT-2103 - Drug Profile; Cisplatin + Taxol - Drug Profile; Cisplatin + Adriamycin - Drug Profile; Pegylated Liposomal Doxorubicin + Trabectedin - Drug Profile; Ovarian Cancer Therapeutics - Drug Profile Updates; Ovarian Cancer Therapeutics - Discontinued Products; Ovarian Cancer Therapeutics - Dormant Products; Ovarian Cancer - Product Development Milestones; Featured News & Press Releases
Appendix: Methodology; Expert Panel Validation; Contact Us; Disclaimer
List of Tables: Number of Products Under Development for Ovarian Cancer, H1 2012; Products under Development for Ovarian Cancer - Comparative Analysis, H1 2012; Number of Products under Development by Companies, H1 2012; Number of Products under Investigation by Universities/Institutes, H1 2012; Comparative Analysis by Late Stage Development, H1 2012; Comparative Analysis by Mid Clinical Stage Development, H1 2012; Comparative Analysis by Early Clinical Stage Development, H1 2012; Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012; Products under Development by Companies, H1 2012; Products under Investigation by Universities/Institutes, H1 2012; Johnson & Johnson, H1 2012; Boehringer Ingelheim GmbH, H1 2012; F. Hoffmann-La Roche Ltd., H1 2012; Abbott Laboratories, H1 2012; Amgen Inc., H1 2012; Sanofi-Aventis, H1 2012; AstraZeneca PLC, H1 2012; Eli Lilly and Company, H1 2012; Viralytics Ltd., H1 2012; GlaxoSmithKline plc, H1 2012; Tekmira Pharmaceuticals Corp., H1 2012; Genentech, Inc., H1 2012; Nektar Therapeutics, H1 2012; Daiichi Sankyo Company, Ltd, H1 2012; Merck & Co., Inc., H1 2012; Micromet, Inc., H1 2012; Generex Biotechnology Corporation, H1 2012; Takeda Pharmaceutical Company Limited, H1 2012; Bio-Path Holdings, Inc., H1 2012; Millennium Pharmaceuticals, Inc., H1 2012; Novartis AG, H1 2012; Samyang Corporation, H1 2012; Aphios Corporation, H1 2012; ImClone Systems Incorporated, H1 2012; Eisai Co., Ltd., H1 2012; ImmunoGen, Inc., H1 2012; OSI Pharmaceuticals, Inc., H1 2012; Cell Therapeutics, Inc., H1 2012; Santaris Pharma A/S, H1 2012; Exelixis, Inc., H1 2012; Aduro BioTech, H1 2012; TopoTarget A/S, H1 2012; Karolinska Institutet, H1 2012; Poniard Pharmaceuticals, Inc., H1 2012; Oncogenex Pharmaceuticals, Inc., H1 2012; Dendreon Corporation, H1 2012; Thallion Pharmaceuticals Inc., H1 2012; Prima BioMed Limited, H1 2012; PharmaGap Inc., H1 2012; Quest PharmaTech Inc., H1 2012; Synta Pharmaceuticals Corp., H1 2012; Oasmia Pharmaceutical AB, H1 2012; Algeta ASA, H1 2012; RXi Pharmaceuticals Corporation, H1 2012; Rexahn Pharmaceuticals, Inc., H1 2012; MabVax Therapeutics, Inc., H1 2012; Morphotek, Inc., H1 2012; Oryzon, H1 2012; GANYMED Pharmaceuticals AG, H1 2012; Abiogen Pharma S.p.A., H1 2012; Glycotope GmbH, H1 2012; BioNumerik Pharmaceuticals, Inc., H1 2012; Indena S.p.A., H1 2012; Alethia Biotherapeutics Inc., H1 2012; Coronado Biosciences, Inc., H1 2012; Heat Biologics, Inc., H1 2012; MacroGenics, Inc., H1 2012; Fresenius Biotech GmbH, H1 2012; Azaya Therapeutics, Inc., H1 2012; CanBas Co., Ltd., H1 2012; Merrimack Pharmaceuticals, Inc., H1 2012; Spirogen Ltd., H1 2012; Neotropix, Inc., H1 2012; Conatus Pharmaceuticals Inc., H1 2012; CritiTech, Inc., H1 2012; BioCancell Therapeutics, Inc., H1 2012; Endocyte, Inc., H1 2012; Advenchen Laboratories, LLC, H1 2012; Onconova Therapeutics, Inc, H1 2012; MolMed S.p.A., H1 2012; Immunotope, Inc., H1 2012; Esperance Pharmaceuticals, Inc., H1 2012; Bolder Biotechnology, Inc., H1 2012; BiPar Sciences, Inc., H1 2012; ImmunoVaccine Technologies Inc., H1 2012; Welichem Biotech Inc., H1 2012; Angstrom Pharmaceuticals, Inc., H1 2012; Vaccinogen, Inc., H1 2012; Cancer Vaccines Limited, H1 2012; NewLink Genetics Corporation, H1 2012; TVAX Biomedical, LLC, H1 2012; Quintessence Biosciences, Inc., H1 2012; arGEN-X BV, H1 2012; Kinex Pharmaceuticals, LLC, H1 2012; Tigris Pharmaceuticals, Inc., H1 2012; Viventia Biotechnologies Inc., H1 2012; TRACON Pharmaceuticals, Inc., H1 2012; Advanced Cancer Therapeutics, H1 2012; Oncolix, Inc., H1 2012; OHR Pharmaceutical Inc., H1 2012; RECEPTA Biopharma S.A., H1 2012; Kyowa Hakko Kirin Pharma, Inc., H1 2012; Vaxonco, H1 2012; Sentinel Oncology Limited, H1 2012; Mebiopharm Co., Ltd., H1 2012; VectorLogics, Inc., H1 2012; ISA Pharmaceuticals B.V., H1 2012; Gradalis Inc., H1 2012; Oncozyme Pharma Inc., H1 2012; Assessment by Monotherapy Products, H1 2012; Assessment by Combination Products, H1 2012; Assessment by Stage and Route of Administration, H1 2012; Assessment by Molecule Type, H1 2012; Ovarian Cancer Therapeutics - Drug Profile Updates; Ovarian Cancer Therapeutics - Discontinued Products; Ovarian Cancer Therapeutics - Dormant Products
List of Figures: Number of Products under Development for Ovarian Cancer, H1 2012; Products under Development for Ovarian Cancer - Comparative Analysis, H1 2012; Products under Development by Companies, H1 2012; Products under Investigation by Universities/Institutes, H1 2012; Late Stage Products, H1 2012; Mid Clinical Stage Products, H1 2012; Early Clinical Stage Products, H1 2012; Discovery and Pre-Clinical Stage Products, H1 2012; Assessment by Monotherapy Products, H1 2012; Assessment by Combination Products, H1 2012; Assessment by Route of Administration, H1 2012; Assessment by Stage and Route of Administration, H1 2012; Assessment by Molecule Type, H1 2012; Assessment by Stage and Molecule Type, H1 2012

Ovarian Cancer - Pipeline Review, H1 2012

Share this report

Other tasks

Research Assistance

Related Markets

Obstetrics/Gynecology Reports

Free Alert Me service